BW A868C

a selective DP receptor antagonist; structure given in first source

Also Known As:

3-benzyl-5-(6-carboxyhexyl)-1-(2-cyclohexyl-2-hydroxyethylamino)hydantoin; BW 868C; BW A 868C; BW-A-868C; BW-A868C; BWA868C; 4-Imidazolidineheptanoic acid, 3-((2-cyclohexyl-2-hydroxyethyl)amino)-2,5-dioxo-1-(phenylmethyl)-

Networked: 9 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - Imidazolidines: 39
        Hydantoins: 306
        BW A868C: 9

Experts

1.	Asirvatham-Jeyaraj, Ninitha: 1 article (12/2019)
2.	Burnett, Robert: 1 article (12/2019)
3.	Fink, Gregory D: 1 article (12/2019)
4.	Jones, A Daniel: 1 article (12/2019)
5.	Bek, Toke: 1 article (08/2015)
6.	Kringelholt, Sidse: 1 article (08/2015)
7.	Oversø Hansen, Pernille: 1 article (08/2015)
8.	Simonsen, Ulf: 1 article (08/2015)
9.	Mak, Oi-Tong: 1 article (11/2011)
10.	Wang, Jun-Jie: 1 article (11/2011)

Related Diseases

1.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/01/2011 - "In the present study, A549 cells, a type of NSCLC (non-small cell lung carcinoma), were treated with PGD2 under various conditions, including while blocking DP and CRTH2/DP2 with the selective antagonists BWA868C and ramatroban respectively. "
2.	Hyperalgesia 09/01/1996 - "Intrathecal administration of BW A868C induced allodynia by itself over a wide range, from 10 pg to 100 ng. " 09/01/1996 - "and the allodynia induced by 100 ng of BW A868C was dose-dependently antagonized by PGD2. " 09/01/1996 - "The blockade of PGE2-induced allodynia by 10 ng of PGD2 was reversed by the potent and selective DP receptor antagonist BW A868C, in a dose-dependent manner. " 10/01/1997 - "3. The blockade of nociceptin-induced allodynia by PGD2 was reversed by the potent and selective DP-receptor antagonist BW A868C in a dose-dependent manner with an ED50 of 42.8 ng kg(-1). "
3.	Pruritus (Itching) 10/01/1996 - "Although the EP1 receptor antagonist AH 6809 and the DP receptor antagonist BW A868C inhibited PGE2- and PGD2-induced itching, respectively, neither antagonist alone significantly affected the itching associated with experimental allergic conjunctivitis. "
4.	Infections 08/01/1996 - "The DP-receptor antagonist, BW A868C, antagonized BW245C concentration-effect (E/[A]) curves, although the corresponding Schild plot had a slope less than unity and displayed a clear infection. "
5.	Hypertension (High Blood Pressure) 12/01/2019 - "Blockade of DP1R with BWA868C, however, increased the magnitude of Ang II-salt hypertension and significantly increased neurogenic pressor activity. " 12/01/2019 - "In a different set of 14-day Ang II-salt-treated rats, mini-osmotic pumps were used to infuse either a nonselective COX (cyclooxygenase) inhibitor ketorolac, L-PGDS inhibitor AT56, or DP1R inhibitor BWA868C to test the role of brain COX-PGD2-DP1R signaling in Ang II-salt hypertension. "

Related Drugs and Biologics

1.	Prostaglandin D2
2.	ramatroban
3.	Ketorolac
4.	NG-Nitroarginine Methyl Ester (L-NAME)
5.	Nitric Oxide Synthase (NO Synthase)
6.	Cyclooxygenase Inhibitors
7.	Interleukin-5 (Interleukin 5)
8.	Interleukin-4 (Interleukin 4)
9.	Salts
10.	Retinaldehyde (Retinal)